Treating cognitive dysfunction in patients with schizophrenia

Journal of Psychiatry and Neuroscience

Volumn 25, Issue 2, 2000, Pages 117-124

  Galletly, Cherrie A ^a   Clark, C Richard ^a   MacFarlane, Alexander C ^b  

^a FLINDERS UNIVERSITY   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Antipsychotic agents; Cognition; Schizophrenia

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE; ZOTEPINE;

COGNITIVE DEFECT; DRUG EFFECT; NEUROPSYCHOLOGICAL TEST; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA;

COGNITION DISORDERS; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0034059964     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Weinberger DR, Gallhofer B. Cognitive function in schizophrenia. Int Clin Psychopharmacol 1997;12(4 Suppl):29S-36S.
2. Rossell SL, David AS. The neuropsychology of schizophrenia: recent trends. Curr Opin Psychiatry 1997;10:26-9.
3. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia: prognosis and predictors of outcome. Arch Gen Psychiatry 1991;48:239-46.
4. Browne S, Roe M, Lane A, Gervin M, Morris M, Kinsella A, et al. Quality of life in schizophrenia - relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand 1996;94:118-24.
5. Brekke JS, Raine A, Ansel M, Lencz T, Bird L. Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia. Schizophr Bull 1997;23:19-28.
6. Braff DL. Information processing and attention dysfunctions in schizophrenia [review]. Schizophr Bull 1993;19(2):233-59.
7. Goldman-Rakic PS, Selemon LD. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull 1997;23:437-58.
8. Hemsley DR. Schizophrenia: a cognitive model and its implications for psychological intervention. Behav Modif 1996;20:139-69.
9. Andreasen NC, O'Leary D, Cizadlo T, Arndt S, Rezai K, Ponto LL, et al. Schizophrenia and cognitive dysmetria: a positron-emission tomography study of dysfunctional prefrontal-thalamic-cerebellar circuitry. Proc Natl Acad Sci U S A 1996;93(18):9985-90.
10. Green MF, Nuechterlein KH. Should schizophrenia be treated as a neurocognitive disorder? Schizophr Bull 1999;25(2):309-18.
11. Goldberg TE, Weinberger DR, Berman KF, Pliskin NH, Podd MH. Further evidence for dementia of the prefrontal type in schizophrenia. Arch Gen Psychiatry 1987;44:1008-14.
12. Wykes T, Reeder C, Corner J, Williams C, Everitt B. The effects of neurocognitive remediation on executive processing in patients with schizophrenia. Schizophr Bull 1999;25(2):291-307.
13. Medalia A, Aluma M, Tryon W, Merriam AE. Effectiveness of attention training in schizophrenia. Schizophr Bull 1998;24:147-52.
14. Bellack AS, Mueser KT, Morrison RL, Tierney A, Podell K. Remediation of cognitive deficits in schizophrenia. Am J Psychiatry 1990;147:1650-5.
15. Stratta P, Mancini F, Mattei P, Daneluzzo E, Bustini M, Casacchia M, et al. Remediation of Wisconsin Card Sorting Test performance in schizophrenia. Psychopathology 1997;30:59-66.
16. Rossell SL, David AS. Improving performance on the WCST: variations on the original procedure. Schizophr Res 1997;28:63-76.
17. Meichenbaum D, Cameron R. Training schizophrenics to talk to themselves. A means of developing attentional controls. Behav Ther 1973;4:515-34.
18. Gold JM, Carpenter C, Randolf C, Goldberg TE, Weiberger DR. Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry 1997;54:159-65.
19. Barcelo F, Sanz M, Molina V, Rubia FJ. The Wisconsin Card Sorting Test and the assessment of frontal function: a validation study with event-related potentials. Neuropsychologia 1997;35:399-408.
20. Berman KF, Ostrem JL, Randolf C, Gold J, Goldberg TE, Coppola R, et al. Physiological activation of a cortical network during performance of the Wisconsin Card Sorting Test: a positron emission tomography study. Neuropsychologia 1995;33:1027-46.
21. Young DA, Freyslinger MG. Scaffolded instruction and the remediation of Wisconsin Card Sorting Test deficits in chronic schizophrenia. Schizophr Res 1995;16:199-207.
22. Kern RS, Wallace CJ, Hellman SG, Womack LM, Green MF. A training procedure for remediating WCST deficits in chronic psychotic patients: an adaptation of errorless learning principles. J Psychiat Res 1996;30:283-94.
23. Bellack AS, Gold JM, Buchanan RW. Cognitive rehabilitation for schizophrenia: problems, prospects and strategies. Schizophr Bull 1999;25(2):257-74.
24. Wiedl KH. Cognitive modifiability as a measure of readiness for rehabilitation. Psychiatr Serv 1999;50(11):1411-9.
25. Corrigan PW, Hirschbeck JN, Wolfe M. Memory and vigilance training to improve social perception in schizophrenia. Schizophr Res 1995;17:257-65.
26. Wykes T, Sturt E. The measurement of social behaviour in psychiatric patients: an assessment of the reliability and validity of the social behaviour schedule. Br J Psychiatry 1986;157:291-307.
27. Delahunty A, Morice R. Rehabilitation of frontal/executive impairments in schizophrenia. Aust N Z J Psychiatry 1996;30:760-7.
28. Hermanutz M, Gestrict J. Computer-assisted attention training in schizophrenia. A comparative study. Eur Arch Psychiatry Clin Neurosci 1991;240:282-7.
29. Benedict RHB, Harris AE, Markow T, McCormick JA, Nuechterlein KH, Asarnow RF. Effects of attention training on information processing in schizophrenia. Schizophr Bull 1994;20(3):537-46.
30. Field C, Galletly C, Anderson D, Walker P. Computer-aided cognitive rehabilitation: possible application to the attentional deficit of schizophrenia. A report of negative results. Percept Mot Skills 1997;85(3 Pt 1):995-1002.
31. Galletly C, Field C. Learning and memory impairment with benzhexol. Aust N Z J Psychiatry 1987;21:612-3.
32. Tune LE, Strauss MS, Lew MF, Breitlinger E, Coyle JT. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am J Psychiatry 1982;139:1460-2.
33. Perlick D, Stastny P, Katz I, Mayer M, Mattis S. Memory deficits and anticholinergic levels in chronic schizophrenia. Am J Psychiatry 1986;143:230-2.
34. Cassens G, Inglis AK, Appelbaum PS, Gutheil TG. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 1990;16:477-99.
35. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993;34:702-12.
36. King DJ, Green JF. Medication and cognitive function in schizophrenia. In: Pantelis C, Nelson HE, Barnes TR, editors. Schizophrenia: a neuropsychological perspective. Chichester (UK): John Wiley; 1996. p. 419-46.
37. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994;36:717-25.
38. Meltzer HY, McGurk SR. The effects of clozapine, risperidone and olanzapine on cognitve function in schizophrenia. Schizophr Bull 1999;25(2):233-55.
39. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999;25(2):201-22.
40. Skarsfeldt T. Differential effect of antipsychotics on place navigation of rats in the Morris water maze. Psychopharmacology 1996;124:126-33.
41. Didriksen M. Effects of antipsychotics on cognitive behaviour in rats using the delayed non-match to position paradigm. Eur J Pharmacol 1995;281:241-50.
42. Saletu B, Grünberger J, Linzmayer L, Anderer P. Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilising pharmaco-EEG and psychometry. Pharmacopsychiatry 1987;20:12-27.
43. Fuji DE, Ahmed I, Jokumsen M, Compton JM. The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients. J Neuropsychiatry Clin Neurosci 1997;9:240-5.
44. Galletly CA, Clark CR, McFarlane AC, Weber DL. Effects of clozapine on non-treatment-resistant patients with schizophrenia. Psychiatr Serv 1999;50:101-3.
45. Goldberg TE, Greenberg RD, Griffin SG, Gold JM, Kleinman JE, Pickar D, et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 1993;162:43-8.
46. Grace J, Bellus SB, Raulin ML, Herz MI, Priest BL, Brenner V. Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning. Psychiatr Serv 1996;47:41-5.
47. Hoff AL, Faustman WO, Wieneke M, Espinoza S, Costa M, Wolkowitz O, et al. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology 1996;15:361-9.
48. Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 1994; 55(Suppl B):82-7.
49. Lezak MD. Neuropsychological assessment. New York: Oxford University Press; 1995.
50. Zahn TP, Pickar D, Haier RJ. Effects of clozapine, fluphenazine and placebo on reaction time measures of attention and sensory dominance in schizophrenia. Schizophr Res 1994;13:133-44.
51. Meyer-Lindenberg A, Gruppe H, Bauer U, Lis S, Krieger S, Gallhofer B. Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study. Pharmacopsychiatry 1997;30:35-42.
52. Galletly CA, Clark CR, McFarlane AC, Weber DL. Relationships between changes in symptom ratings, neuropsychological test performance and quality of life in schizophrenic patients treated with clozapine. Psychiatry Res 1997;72:159-61.
53. Rossi A, Mancini F, Stratta P, Mattei P, Gismondi R, Pozzi F, et al. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr Scand 1997;95:40-3.
54. Stip E, Lussier I, Babai M, Fabian JL. Seroquel and cognitive improvement in patients with schizophrenia. Biol Psychiatry 1996;40:430-7.
55. Green MF, Marshall BD, Wirshing WC, Ames D, Marder SR, McGurk S, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997;154:799-804.
56. Daniel DG, Goldberg TE, Lubick LJ, Weinberger DR, Kleinman JE, Pickar D, et al. Self-reported cognitive impairment predicts patient preference between risperidone and clozapine. Schizophr Res 1995;15:147-8.
57. Gallhofer B, Bauer U, Gruppe H, Krieger S, Lis S. First episode schizophrenia: the importance of compliance and preserving cognitive function. J Pract Psychiatry Behav Health 1996;2:16S-24S.
58. Fleming K, Kahali A, Yeh C, Vargo DL, Thyrum PT, Potkin S. Neurocognitive effects of 'Seroquel' (ICI204, 636) [abstract]. 10th World Congress of Psychiatry, Madrid, Aug. 23-28, 1996.
59. Stip E, Lussier I, Babai M, Fabian JL. Seroquel and cognitive improvement in patients with schizophrenia. Biol Psychiatry 1996; 40:34-5.
60. Hagger C, Mitchell D, Wise AL, Schulz SC. Effects of oral ziprasidone and risperidone on cognitive functioning in patients with schizophrenia or schizoaffective disorder: preliminary data [abstract]. Eur Neuropsychopharmacol 1997; 7(Suppl 2):S219.
61. Rosenheck R, Tekell J, Peters J, Cramer J, Fontana A, Xu W, et al. Does participation in psychosocial treatment augment the benefit of clozapine? Arch Gen Psychiatry 1998;55:618-25.